Tip os
Log ind
ALK produktion4-red.jpg

ALK: Pill gets positive mention

Top picks in English:

Pill against house dust mite allergy receives positive review in US medical journal


BY THOMAS BO CHRISTENSEN
Offentliggjort 27.04.16 kl. 11:42

Log ind for at læse artikler

Velkommen til MedWatch. En del af vores indhold er eksklusivt og forbeholdt vores brugere.

Prøv os gratis i 14 dage

Få fuld adgang til vores kvalitetsjournalistik med et gratis prøveabonnement.

Sign up for MedWatch newsletter
Mest læste Top picks in English

Here is what Danish drug companies pay their workers

Løn Top picks in English:

The average monthly salary in the private pharmaceutical industry in Denmark is DKK 57,109. Make the jump to find out which company pays the highest wages and learn how much the rest of the industry pays as well.

Leo Pharma invests in US biotech company

Top picks in English:

The Danish dermatology company Leo Pharma has pumped money into a US based biotech company developing a medical device mainly to be used in treatments of a hair loss disease. It is also the first agreement made from Leo’s newly founded hub in Boston.

FDA panel sees cardiovascular benefits from Novo's Victoza

Top picks in English:

With an overwhelming majority, an independent advisory committee under the US drug agency FDA has found that Novo Nordisk’s Leader study provides substantial evidence of cardiovascular risk reduction in treatment with Victoza. The result opens up the opportunity for including the data on the product’s US label.

Novo: Not shying away from conflict

Top picks in English:

13 years ago, Novo Nordisk was met with a barrage of criticism for its participation in a trial against the South African government. A new conflict between the industry and the government has now broken out. Novo will have no part of it, but is not shying away from the conflict, stresses press chief.

Lundbeck Foundation company goes public

Top picks in English:

Lundbeckfonden Ventures’ portfolio company Bonesupport has listed on the Swedish stock market and raised SEK 500 million (about USD 57 million). The IPO puts a period to a busy half year, where two other companies have been sold. New investments are coming up, says managing partner Mette Kirstine Agger.

Novo Nordisk considers teaming up with the food industry

Top picks in English:

Novo Nordisk does not only aim to treat obesity, but also potentially to prevent it. The strategy could lead to new types of partnerships, for instance with the food industry, says CEO Lars Fruergaard Jørgensen.

Forsiden lige nu

De første studieresultater: Overvægtige taber sig med Novo Nordisks fedmehåb

COLOURBOX524861.JPG Medicinal & Biotek:

Novo Nordisk fører an i jagten på at udvikle medicin, som kan smelte kilo af overvægtige kroppe. Spritnye resultater for GLP-1-analogen Semaglutid viser de første gode takter for medicinalkoncernens næste fedmehåb. (opdateret)

MedWatch-indeks: Gode nyheder giver overvægt af grønt

Medicinal & Biotek:

Studieresultater og medvind fra FDA såvel som EMA sender det danske life science-indeks op i en overvægt af grønne tal, selv ikke den dårligste nyhed formår at sende det ansvarlige selskab i rødt.

Lundbeck-direktør: Jeg var klar over, at FDA så det på en anden måde

Medicinal & Biotek:

Om Lundbeck vil forsøge en tredje gang at få udvidet indlægssedlen på antidepressivet Trintellix i USA er endnu uvist, siger forskningsdirektør Anders Gersel Pedersen for hvem, nattens afslag fra FDA ikke var en fuldstændig overraskelse.

Novo står til længe ventet labelopdatering i Europa

Medicinal & Biotek:

Novo Nordisk er godt på vej til at kunne medtage data fra det vigtige hjerte-kar-studie Leader i indlægssedlen for diabetesblockbusteren Victoza i Europa efter en positiv anbefaling fra CHMP.

Amerikanere godkender blodkræftmiddel fra Roche

Medicinal & Biotek:

Roches storsælgende kræftmiddel Rituxan har af de amerikanske lægemiddelmyndigheder fået grønt lys til tre former for blodkræft.

FDA puster til patentstrid med ny godkendelse

Medicinal & Biotek:

De amerikanske lægemiddel-myndigheder har godkendt den første behandling af sjælden sygdom, der kan administreres af patienten selv. Det sker midt i patentslagsmål med midlet som centrum.

ANNONCE
ANNONCE


ANNONCE